Epithelial Barrier Repair Proteins for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD) primarily focus on suppressing inflammation without addressing the restoration of epithelial barrier function, which is crucial for disease management.
Innovation Solution
Development of novel protein therapeutics, such as SG-15, SG-16, SG-17, and SG-18, encoded by Eubacterium eligens and Clostridium bartlettii, which enhance epithelial barrier integrity and reduce inflammation by promoting intestinal barrier repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current therapies focus on suppressing inflammation, then inflammatory response is reduced, but epithelial barrier function is not restored
Solution Approach 1:
The therapeutic approach is segmented into two distinct functional components: one that suppresses inflammation and another that actively promotes epithelial barrier repair. This is achieved by using separate protein therapeutics (e.g., anti-inflammatory cytokines combined with barrier-repair proteins) that can be administered together or sequentially, allowing each component to address its specific target without interfering with the other's mechanism of action.
Solution Approach 2:
The patent combines multiple therapeutic functions into a single comprehensive treatment regimen. By merging anti-inflammatory therapy with epithelial barrier repair therapy, the treatment addresses both the harmful inflammatory response and the compromised barrier function simultaneously, creating a synergistic effect that resolves the contradiction between reducing inflammation and restoring barrier integrity.
2Object-affected harmful factors
If narrow therapeutic mode targets only inflammation, then inflammatory symptoms are suppressed, but epithelial barrier integrity is disregarded
Solution Approach 1:
The therapeutic regimen is designed with multi-functionality, where the treatment protocol can address multiple aspects of IBD pathophysiology. The universal approach allows clinicians to select from various protein therapeutics that can target inflammation, barrier repair, or both simultaneously, making the therapeutic strategy adaptable to different disease presentations and patient needs while expanding the overall therapeutic scope beyond narrow anti-inflammatory focus.
3Reliability
If protein therapeutic lacks stability through manufacturing and storage, then production is difficult, but therapeutic efficacy is compromised
Solution Approach 1:
The patent employs parameter changes in the form of protein engineering modifications to enhance stability. Specific amino acid substitutions, additions of stabilizing domains, or modification of post-translational modification sites can alter the protein's physical and chemical properties, making it more resistant to degradation during manufacturing, storage, and administration while preserving its biological activity and therapeutic efficacy.
Data Source
AI summary
The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.